Nicotine Replacement Therapy at 50: Why the Best Cessation Tools Are Still Underused

Nicotine replacement therapy is one of the safest, most thoroughly studied, and most effective medical interventions ever developed. It's available without a prescription in most countries. It's recommended by every major health organization on Earth as a first-line treatment for tobacco dependence. It doubles or triples a smoker's odds of quitting successfully compared to unassisted attempts. And yet, in any given year, fewer than 10% of smokers who try to quit use it. The majority of quit attempts—roughly two-thirds—are made cold turkey, with no pharmacological support whatsoever, despite a long-term success rate of 3–5%. The most effective, accessible cessation tool ever invented is being systematically underutilized by the population it was designed to help. The reasons are a tangle of economics, psychology, healthcare system failure, and the stubborn persistence of the idea that quitting should be hard to be real.

The evidence for NRT's effectiveness is among the most robust in all of behavioral medicine. The Cochrane Collaboration's systematic reviews, which pool data from over 150 randomized controlled trials involving more than 50,000 participants, consistently find that all forms of NRT—patch, gum, lozenge, inhaler, nasal spray—increase the odds of quitting by 50–70% compared to placebo. Combination NRT (patch plus a faster-acting form like gum or lozenge) is more effective than single-form NRT, increasing quit rates further. NRT is safe: the risks of nicotine without combustion are minimal for most adults, and the cardiovascular concerns that once limited NRT use in patients with heart disease have been largely resolved by modern safety data. NRT is cost-effective: the cost of a course of NRT is a fraction of the healthcare costs of continued smoking. And NRT is, by pharmaceutical standards, a remarkably clean drug—nicotine doesn't interact with other medications, doesn't cause organ damage at therapeutic doses, and has a well-understood pharmacokinetic profile. Yet it remains peripheral to most quit attempts.

The economic barriers to NRT access are real and regressive. In the United States, a two-week supply of nicotine patches costs $30–$60 over the counter—comparable to a pack-a-day cigarette habit in low-tax states, and a significant upfront cost for low-income smokers who may not have the cash flow to invest in a quit attempt. Some insurance plans cover NRT with a prescription, but many don't, and the prescription requirement itself is a barrier for smokers who lack a regular healthcare provider or can't afford a doctor's visit. In the UK, NRT is available on prescription at reduced cost through the NHS, and quitlines distribute free NRT to eligible callers—policies that have dramatically increased NRT utilization and contributed to the UK's declining smoking rates. The lesson is clear: when NRT is free or cheap, more smokers use it, and more quit. When it's expensive, fewer use it, and fewer quit. The economics are not complicated. The politics of subsidizing nicotine for smokers are.

The psychological barriers to NRT use are equally significant and more deeply rooted. Many smokers believe—incorrectly—that NRT is just as harmful as smoking ('you're just replacing one addiction with another'), that NRT doesn't work ('I tried the patch once and it didn't help'), or that using NRT is cheating ('if I can't quit on my own, I'm weak'). These beliefs are reinforced by a culture that moralizes smoking cessation, celebrating the heroic cold-turkey quitter while implicitly dismissing pharmacologically-assisted quitting as somehow less authentic. The reality is that cold-turkey quitting works for a small minority of smokers, typically those with lower levels of dependence, and that for the majority who are more heavily dependent, pharmacological support is not a crutch but a necessary bridge between addiction and recovery. The 'just try harder' approach to smoking cessation is about as effective as 'just try harder' would be for any other chronic medical condition—which is to say, not very.

The healthcare system's failure to consistently deliver NRT to smokers who need it is a systemic quality-of-care problem that receives remarkably little attention. Primary care physicians, who see the majority of smokers, spend an average of less than three minutes discussing smoking during an annual visit, and fewer than half of smokers report ever having been advised by a doctor to quit. When cessation is addressed, it's often limited to a brief admonition ('you should quit') without a specific treatment recommendation or prescription. The reasons are structural: smoking cessation counseling is poorly reimbursed, physicians receive minimal training in addiction medicine, and the 15-minute primary care visit doesn't accommodate the kind of shared decision-making and follow-up that effective cessation support requires. The result is a healthcare system that treats smoking as a risk factor to be noted in the chart rather than a medical condition to be treated.

The future of NRT may lie outside the traditional pharmaceutical framework. Nicotine pouches, which deliver nicotine without tobacco or combustion and share many pharmacological properties with NRT, are blurring the line between cessation aid and consumer product. Several public health researchers have proposed that nicotine products should be regulated along a risk continuum—with combustible cigarettes at the high-risk end, NRT at the low-risk end, and e-cigarettes and nicotine pouches somewhere in between—rather than in the binary pharmaceutical/tobacco framework that currently governs most jurisdictions. In this model, the goal is to move nicotine users down the risk continuum, and the regulatory framework is designed to make lower-risk products more accessible, more affordable, and more appealing than higher-risk ones. NRT, in such a framework, would be treated less as a medication and more as a consumer good—priced competitively, marketed honestly, and made universally available. Whether that's an improvement or a surrender depends on whether you believe the goal is a nicotine-free world or a smoke-free one.

NRT is not a magic bullet. It roughly doubles the odds of quitting, which means that even with NRT, the majority of quit attempts still fail. The absolute quit rates—typically 7–10% sustained abstinence at one year—are sobering and reflect the biological reality that nicotine addiction is a chronic, relapsing condition. But NRT is the best tool we have that's been studied with the rigor of pharmaceutical regulation, proven safe over decades of post-market surveillance, and made available without the barriers that limit access to prescription medications. The fact that it's used by fewer than one in ten smokers attempting to quit is not an indictment of NRT. It's an indictment of a system that makes the most effective cessation tool inaccessible, unaffordable, or psychologically unacceptable to the people who need it most. Making NRT as easy to get as cigarettes—and as cheap, and as un-stigmatized—would be the single most impactful cessation intervention we could implement tomorrow. The evidence has been clear for decades. The implementation has not.